Search: WFRF:(Howlett Jonathan G) >
Effects of dapaglif...
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
-
Docherty, Kieran F (author)
-
Jhund, Pardeep S (author)
-
Inzucchi, Silvio E (author)
-
show more...
-
Köber, Lars (author)
-
Kosiborod, Mikhail N (author)
-
Martinez, Felipe A (author)
-
Ponikowski, Piotr (author)
-
DeMets, David L (author)
-
Sabatine, Marc S (author)
-
Bengtsson, Olof (author)
-
Sjöstrand, Mikaela (author)
-
Langkilde, Anna Maria, 1955 (author)
-
Desai, Akshay S (author)
-
Diez, Mirta (author)
-
Howlett, Jonathan G (author)
-
Katova, Tzvetana (author)
-
- Ljungman, Charlotta, 1977 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
O´Meara, Eileen (author)
-
Petrie, Mark C (author)
-
Schou, Morten (author)
-
Verma, Subodh (author)
-
Vinh, Pham Nguyen (author)
-
Solomon, Scott D (author)
-
McMurray, John J V (author)
-
show less...
-
(creator_code:org_t)
- 2020-03-28
- 2020
- English.
-
In: European heart journal. - : Oxford University Press (OUP). - 1522-9645 .- 0195-668X. ; 41:25, s. 2379-2392
- Related links:
-
https://academic.oup...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy.In this post hoc analysis, we examined the effect of study treatment in the following yes/no subgroups: diuretic, digoxin, mineralocorticoid receptor antagonist (MRA), sacubitril/valsartan, ivabradine, implanted cardioverter-defibrillating (ICD) device, and cardiac resynchronization therapy. We also examined the effect of study drug according to angiotensin-converting enzyme inhibitor/angiotensin receptor blocker dose, beta-blocker (BB) dose, and MRA (≥50% and <50% of target dose). We analysed the primary composite endpoint of cardiovascular death or a worsening HF event. Most randomized patients (n=4744) were treated with a diuretic (84%), renin-angiotensin system (RAS) blocker (94%), and BB (96%); 52% of those taking a BB and 38% taking a RAS blocker were treated with ≥50% of the recommended dose. Overall, the dapagliflozin vs. placebo hazard ratio (HR) was 0.74 [95% confidence interval (CI) 0.65-0.85] for the primary composite endpoint (P<0.0001). The effect of dapagliflozin was consistent across all subgroups examined: the HR ranged from 0.57 to 0.86 for primary endpoint, with no significant randomized treatment-by-subgroup interaction. For example, the HR in patients taking a RAS blocker, BB, and MRA at baseline was 0.72 (95% CI 0.61-0.86) compared with 0.77 (95% CI 0.63-0.94) in those not on all three of these treatments (P-interaction 0.64).The benefit of dapagliflozin was consistent regardless of background therapy for HF.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- Heart failure
- Heart failure and reduced ejection fraction
- SGLT2 inhibitor
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Docherty, Kieran ...
-
Jhund, Pardeep S
-
Inzucchi, Silvio ...
-
Köber, Lars
-
Kosiborod, Mikha ...
-
Martinez, Felipe ...
-
show more...
-
Ponikowski, Piot ...
-
DeMets, David L
-
Sabatine, Marc S
-
Bengtsson, Olof
-
Sjöstrand, Mikae ...
-
Langkilde, Anna ...
-
Desai, Akshay S
-
Diez, Mirta
-
Howlett, Jonatha ...
-
Katova, Tzvetana
-
Ljungman, Charlo ...
-
O´Meara, Eileen
-
Petrie, Mark C
-
Schou, Morten
-
Verma, Subodh
-
Vinh, Pham Nguye ...
-
Solomon, Scott D
-
McMurray, John J ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
European heart j ...
- By the university
-
University of Gothenburg